Novavax (Finally) Prepares for Takeoff in the U.S.
May 31, 2022
(Axios) – As one of America’s first big bets under Operation Warp Speed, Novavax’s COVID vaccine is notably late to the party as the Maryland biotech seeks a potential FDA emergency use authorization for its COVID shot. But company leaders say they see a clear runway to market success for its protein-based product — not only as a booster for the vaccinated but as an alternative first-line defense for those who’ve refused mRNA shots. (Read More)